Xencor, Inc. (XNCR) News
Follow Xencor, Inc. (XNCR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 13 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Xencor Price Target Raised to $29.00/Share From $27.00 by Truist Securities
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 03:29 PM UTC
L
Truist Securities reiterates Buy rating on Xencor, $29 price target
Truist Securities reiterated their Buy rating on Xencor's stock with a price target of $29.00.The price target implies an upside of 21.8% from the Sep 25 close of $23.80.Key takeaways from the analyst noteEncouraging Cli
EQUITY | Sep 28, 2026, 03:18 PM UTC
L
XNCR late-stage T-cell engager programs advance; pivotal data eyed soon
Session coverage says XNCR is moving its T-cell engager and immunology programs into late-stage development, with pivotal readouts expected at ESMO and in phase II-B UC studies.
EQUITY | Sep 09, 2026, 04:21 PM UTC
L
XNCR flags strategic shift to proprietary late-stage XmAb RCC development
Company discussion points to a strategic shift toward late-stage development of proprietary XmAb molecules, citing pivotal RCC data for an ENPP3 T-cell engager and expected ESMO timing.
EQUITY | Sep 09, 2026, 03:49 PM UTC
L
JP Morgan lifts Xencor price target to $21 from $14
JP Morgan raised its Xencor price target to $21.00 per share from $14.00, while maintaining the stock at Neutral, per TradingView News via Benzinga.
EQUITY | Sep 03, 2026, 09:20 PM UTC
L
XNCR - Xencor to Present at the 2026 Cantor Global Healthcare Conference
XNCR - Xencor to Present at the 2026 Cantor Global Healthcare Conference
EQUITY | Sep 02, 2026, 08:04 PM UTC
L
Xencor management set to present at Cantor Global Healthcare Conference
Xencor, Inc. (NASDAQ:XNCR) said management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m.
EQUITY | Sep 02, 2026, 08:01 PM UTC
L
Raymond James raises Xencor price target to $46 from $40
Raymond James raised its Xencor price target to $46.00 per share from $40.00 and maintained a Strong Buy rating, per TradingView News via Benzinga.
EQUITY | Sep 01, 2026, 03:53 PM UTC
L
XNCR - Xencor Reports Second Quarter 2026 Financial Results
XNCR - Xencor Reports Second Quarter 2026 Financial Results
EARNINGS | Aug 05, 2026, 08:04 PM UTC
H
WBLR Updates Analyst Conviction List
Adds and removes stocks from conviction list
EQUITY | Aug 03, 2026, 11:59 AM UTC
H
Xencor to receive $105M from Alexion
Xencor gets $105M from Alexion
EQUITY | Jul 29, 2026, 08:02 PM UTC
L
XNCR Xencor announces proffered Paper oral presentation at esmo 2026 for phase 1 clinical study of xmab819 in advanced clear cell renal cell
XNCR Xencor announces proffered Paper oral presentation at esmo 2026 for phase 1 clinical study of xmab819 in advanced clear cell renal cell carcinoma
EQUITY | Jul 17, 2026, 01:11 PM UTC
H
Xencor price target lowered to $27 from $29 at Truist
Truist lowered the firm's price target on Xencor to $27 from $29 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is antic
EARNINGS | Jul 07, 2026, 01:15 PM UTC